We are live on
!
Find out more
VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$160M
1-Year Est. Return
517.12%
This Fund
S&P 500
This Quarter
Est. Return
+21.8%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$8.94M
(+8.4%)
Cap. Flow
+$3.84M
Cap. Flow
% of AUM
3.32%
Top 10 Holdings %
Top 10 Hldgs %
86.64%
Holding
50
New
32
Increased
4
Reduced
2
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$6.48M |
| 2 |
Perspective Therapeutics
CATX
|
+$4.08M |
| 3 |
Protara Therapeutics
TARA
|
+$3.25M |
| 4 |
TRML
Tourmaline Bio
TRML
|
+$2.33M |
| 5 |
Nurix Therapeutics
NRIX
|
+$2.24M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$3.67M |
| 2 |
SCPH
scPharmaceuticals
SCPH
|
+$2.36M |
| 3 |
Context Therapeutics
CNTX
|
+$2.08M |
| 4 |
TELA Bio
TELA
|
+$1.89M |
| 5 |
OPTN
OptiNose
OPTN
|
+$1.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alector
ALEC
$240M
| $104K | 0.09% |
+55,000
| New | +$207K |
|
|
27
Context Therapeutics
CNTX
$43.2M
| $94.5K | 0.08% |
90,000
-1,200,323
| -93% | -$2.08M |
|
|
TERN
28
DELISTED
Terns Pharmaceuticals
TERN
| $94.2K | 0.08% |
+17,000
| New | +$115K |
|
|
VTYX
29
DELISTED
Ventyx Biosciences
VTYX
| $76.7K | 0.07% |
+35,000
| New | +$79.3K |
|
30
Enanta Pharmaceuticals
ENTA
$393M
| $74.8K | 0.06% |
+13,000
| New | +$125K |
|
31
Larimar Therapeutics
LRMR
$454M
| $69.7K | 0.06% |
+18,000
| New | +$119K |
|
32
Gossamer Bio
GOSS
$86.8M
| $67.8K | 0.06% |
+75,000
| New | +$64.3K |
|
33
Aclaris Therapeutics
ACRS
$860M
| $67K | 0.06% |
+27,000
| New | +$67.2K |
|
34
Ovid Therapeutics
OVID
$489M
| $65.4K | 0.06% |
+70,000
| New | +$78.3K |
|
35
4D Molecular Therapeutics
FDMT
$621M
| $55.7K | 0.05% |
+10,000
| New | +$78.5K |
|
36
Sutro Biopharma
STRO
$353M
| $55.2K | 0.05% |
+3,000
| New | +$91.6K |
|
37
PMV Pharmaceuticals
PMVP
$67.2M
| $52.9K | 0.05% |
+35,000
| New | +$55.4K |
|
|
KYNB
38
Kyntra Bio
KYNB
$28.7M
| $42.4K | 0.04% |
+3,200
| New | +$29.7K |
|
39
CytomX Therapeutics
CTMX
$760M
| $36K | 0.03% |
+35,000
| New | +$37.7K |
|
|
KRON
40
DELISTED
Kronos Bio
KRON
| $33.3K | 0.03% |
+35,000
| New | +$33K |
|
41
Karyopharm Therapeutics
KPTI
$46M
| $27.1K | 0.02% |
+2,667
| New | +$32.2K |
|
42
Bolt Biotherapeutics
BOLT
$6.63M
| $26.8K | 0.02% |
+2,500
| New | +$30.2K |
|
|
ELEV
43
DELISTED
Elevation Oncology
ELEV
| $25.3K | 0.02% |
+45,000
| New | +$26.6K |
|
44
Cocrystal Pharma
COCP
$15.4M
| $20.2K | 0.02% |
+10,000
| New | +$20K |
|
45
NextCure
NXTC
$37.4M
| $19.3K | 0.02% |
+2,083
| New | +$30.6K |
|
|
OPTN
46
DELISTED
OptiNose
OPTN
| – | – |
-143,107
| Closed | -$1.44M |
|
|
SCPH
47
DELISTED
scPharmaceuticals
SCPH
| – | – |
-517,668
| Closed | -$2.36M |
|
|
48
TELA Bio
TELA
$32.3M
| – | – |
-747,410
| Closed | -$1.89M |
|
49
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| – | – |
-150,000
| Closed | -$14.8M |
|
50
Skye Bioscience
SKYE
$19.3M
| – | – |
-211,071
| Closed | -$825K |
|
Similar funds
BFAG
SLG
SMF
LCA
SGCM
RP
PCC
RCWM
Velan Capital Investment Management's Q4 2024 Portfolio in Review
As of Q4 2024, Velan Capital Investment Management held 50 positions worth $116M, up 8.4% from $107M the previous quarter. Its ten largest holdings account for 87% of the portfolio.
Velan Capital Investment Management deployed $3.84M of net new capital in Q4 2024, opening 32 new positions and adding to 4 existing holdings. Its largest new stake was SpringWorks Therapeutics: 185,520 shares worth $6.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 86% a quarter earlier.
On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $3.67M trimmed.
- Velan Capital Investment Management's largest Q4 2024 buy was SpringWorks Therapeutics: 185,520 shares worth $6.7M.
- Velan Capital Investment Management added most to Protara Therapeutics in Q4 2024, an estimated $3.25M increase.
- Velan Capital Investment Management's biggest Q4 2024 reduction was Praxis Precision Medicines, cutting an estimated $3.67M.
- Velan Capital Investment Management fully exited scPharmaceuticals in Q4 2024, selling an estimated $2.36M.
- Velan Capital Investment Management's ten largest holdings make up 87% of its $116M portfolio in Q4 2024.
- Velan Capital Investment Management opened 32 new positions and closed 5 in Q4 2024.
- Velan Capital Investment Management's portfolio value rose 8.4% quarter-over-quarter to $116M.
Based on Velan Capital Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.